Tokyo Tape
Sign in
← Santen Pharmaceutical

Quarterly report · Q2

4536.TEDINET S100S66I
Period2023-04-01 → 2023-09-30
Filed2023-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥145.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥73.4bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥279.0bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥128.9bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥63.4bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥25.1bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥12.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income−¥19.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income−¥27.4bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥24.1bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥11.2bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax−¥5.8bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥19.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥28.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥19.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.9bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥14.9bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥22.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥28.7bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥19.3bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥8.9bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥22.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income−¥28.7bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥427.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥421.2bnat 2023-03-31Cons.Assets IFRS
Total assets¥426.6bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥120.5bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥127.9bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥306.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥293.3bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥309.4bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥336.8bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥307.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥294.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥310.1bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥64.7bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥57.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥69.1bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥83.0bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥27.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥37.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥18.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥26.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥18.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥19.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥37.2bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥16.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥52.062023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥24.62023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-38.62022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-56.052022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-75.562022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥51.922023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥24.522023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-38.62022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-56.052022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-75.562022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 674
ItemContextValueUnit
Selling general and administrative expenses IFRSPrior1YTDDuration42296000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration43174000000JPY
Research and development expenditure recognized as expense during period IFRSPrior1YTDDuration14267000000JPY
Research and development expenditure recognized as expense during period IFRSCurrentYTDDuration12461000000JPY
Amortization on intangible assets associated with products IFRSPrior1YTDDuration5166000000JPY
Amortization on intangible assets associated with products IFRSCurrentYTDDuration4699000000JPY
Other income IFRSPrior1YTDDuration260000000JPY
Other income IFRSCurrentYTDDuration1211000000JPY
Other expenses IFRSPrior1YTDDuration30566000000JPY
Other expenses IFRSCurrentYTDDuration2128000000JPY
Operating profit loss IFRSPrior1YTDDuration-19021000000JPY
Operating profit loss IFRSCurrentYTDDuration25099000000JPY
Finance income IFRSPrior1YTDDuration1245000000JPY
Finance income IFRSCurrentYTDDuration1123000000JPY
Finance costs IFRSPrior1YTDDuration262000000JPY
Finance costs IFRSCurrentYTDDuration575000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-1064000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-1573000000JPY
Profit loss before tax IFRSPrior1YTDDuration-19103000000JPY
Profit loss before tax IFRSCurrentYTDDuration24075000000JPY
Income tax expense IFRSPrior1YTDDuration2917000000JPY
Income tax expense IFRSCurrentYTDDuration4800000000JPY
Profit loss IFRSPrior1YTDDuration-22019000000JPY
Profit loss IFRSCurrentYTDDuration19274000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration2092000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration1245000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration10052000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration9091000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration－JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-23000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration1464000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration1010000000JPY
Other comprehensive income IFRSPrior1YTDDuration13607000000JPY
Other comprehensive income IFRSCurrentYTDDuration11323000000JPY
Comprehensive income IFRSPrior1YTDDuration-8412000000JPY
Comprehensive income IFRSCurrentYTDDuration30597000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration-22041000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration19280000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration22000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-6000000JPY
Profit loss IFRSPrior1YTDDuration-22019000000JPY
Profit loss IFRSCurrentYTDDuration19274000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration-8400000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration30650000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration-12000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration-53000000JPY
Comprehensive income IFRSPrior1YTDDuration-8412000000JPY
Comprehensive income IFRSCurrentYTDDuration30597000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration-56.05
Basic earnings loss per share IFRSCurrentYTDDuration52.06

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass